Welcome to our dedicated page for Becton Dickinson & news (Ticker: BDX), a resource for investors and traders seeking the latest updates and insights on Becton Dickinson & stock.
Becton, Dickinson and Company reports developments for a global medical technology business organized around medical essentials, connected care, biopharma systems and interventional products. Company news commonly covers fiscal results, guidance, dividends, share repurchases, debt retirement, executive appointments and strategy updates following the completed separation of the Biosciences and Diagnostic Solutions business.
BD updates also include product and customer developments across its care-delivery platforms. Recent themes include the BD® CentroVena One™ Insertion System for central venous catheter placement, BD Pyxis™ Pro medication dispensing technologies, BD Alaris™ Infusion Systems, vascular access products, medication management, patient-safety workflows and partnerships with health systems.
BD (NYSE: BDX) announced the BD Vacutainer® Urine Complete Cup Kit on February 23, 2026, a three-tube urine collection system designed to preserve specimen integrity, reduce repeat collections, and streamline testing workflows.
The kit includes culture, urinalysis, and discard tubes, a sterile cup with integrated transfer device, and a Castile wipe. Available in the United States with Hemogard and conventional stoppers and compatible with automated workflows; orders available through local sales representatives.
BD (NYSE: BDX) named Lanesha Minnix executive vice president and general counsel, effective March 16, 2026. Minnix will lead the Law Group and Public Affairs, report to Tom Polen, and join the BD Executive Leadership Team. She joins from Walgreens Boots Alliance, where she helped lead a $24 billion take-private transaction and oversaw legal, corporate affairs, risk, security and EHS. Minnix previously held senior roles at Ecolab and Flowserve and holds a JD and MBA from the University of Tulsa and a BS in Business Administration from Saint Louis University.
Becton, Dickinson and Company (NYSE: BDX) commenced tender offers to purchase up to $1,600,000,000 aggregate purchase price of specified outstanding senior notes across multiple series.
Key dates: Early Tender Date Feb 24, 2026, Reference pricing Feb 25, 2026, Expiration Mar 11, 2026, anticipated settlement Mar 13, 2026 (early settlement possible Feb 27, 2026). Early tender payments are $30 per $1,000 for eligible tenders. Offer SubCaps include $1,000,000,000 for 4.669% 2047 and $450,000,000 for one 2044 series. Acceptance priority levels and fixed spreads per series determine allocation and Total Consideration.
BD (NYSE: BDX) completed the spin-off and combination of its Biosciences & Diagnostic Solutions business with Waters Corporation (NYSE: WAT) on Feb 9, 2026. BD received $4.0 billion in cash and shareholders received ~0.135 WAT shares per BDX share, with cash for fractions.
As of closing BD shareholders held 39.2% of the combined company (fully diluted). Based on WAT's Feb 6, 2026 close, the business was valued at $18.8 billion. BD expects to use $2.0 billion for an accelerated share repurchase and $2.0 billion to repay debt. Claire M. Fraser joined the Waters board and stepped down from the BD board.
Waters (NYSE: WAT) has completed its combination with Becton, Dickinson and Company's Biosciences & Diagnostic Solutions businesses, creating a global life sciences and diagnostics leader organized into four divisions: Waters Analytical Sciences, Waters Biosciences, Waters Advanced Diagnostics, and Waters Materials Sciences. The transaction used a Reverse Morris Trust, and post-close ownership is Waters 60.8% and BD shareholders 39.2% on a fully diluted basis. Claire M. Fraser, Ph.D., joined the Waters Board, expanding it to 11 members. Barclays advised Waters; Kirkland & Ellis served as lead counsel.
BD (NYSE: BDX) reported Q1 FY2026 revenue of $5.25B, up 1.6% reported (0.4% FXN), and reported diluted EPS $1.34 (+28.8%); adjusted diluted EPS was $2.91 (down 15.2%).
The company expects the Biosciences and Diagnostic Solutions combination with Waters to close Feb 9, 2026, and affirmed full-year New BD guidance: low single-digit revenue growth and adjusted diluted EPS of $12.35–$12.65.
BD (NYSE: BDX) and Envetec completed a joint feasibility pilot demonstrating closed-loop recycling of polystyrene Petri dishes into new manufacturing feedstock.
The study processed plated media as post-industrial material through Envetec's GENERATIONS chemical disinfection to produce clean polymer flakes, extruded into pellets and molded into Petri dish prototypes.
BD (NYSE: BDX) declared a quarterly cash dividend of $1.05 per common share, payable March 31, 2026, to holders of record on March 10, 2026, equal to an indicated annual dividend of $4.20 per share. The company has repurchased $250 million of BD stock to date in fiscal 2026. The board also authorized repurchases of up to 10 million additional shares of common stock, to be executed via open market purchases, privately negotiated transactions or other methods. Management will determine the timing, manner, number and value of repurchases at its discretion and subject to market, economic and business considerations.
BD (NYSE: BDX) will host an audio webcast at 8:00 a.m. ET on Monday, February 9, 2026 to discuss financial results for its first quarter of fiscal 2026 (period ended December 31, 2025) and to provide an update on operations and strategy. Prior to the call, the company will issue a news release and presentation materials including summary financial information.
The live audio webcast and subsequent replay will be available at www.bd.com/investors.
Waters (NYSE: WAT) shareholders approved issuing Waters common stock to shareholders of Becton, Dickinson and Company (NYSE: BDX) for the proposed combination of BD's Biosciences & Diagnostic Solutions business with Waters, with preliminary voting showing ~99% support.
Waters and BD received all required regulatory approvals and BD obtained a favorable IRS Private Letter Ruling on U.S. federal tax matters. The transaction is expected to close on February 9, 2026, subject to customary closing conditions. Waters will release Q4 2025 results and hold a conference call and webcast on February 9, 2026 at 8:30 a.m. ET; a replay will be available through at least March 9, 2026.